Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?

Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.

Hospices can’t handle the growing number of patients who need wound care

A few years ago, I worked with a patient close to 100 years old. She had diabetes for most of her adult life, which affected

November 24, 2023

Rare disease biotech Rallybio cuts 19 staffers and sheds partnered preclinical programs

Rallybio is laying off close to half of its employees and seeking “alternative options” for its preclinical programs as it gets ready to put the

February 7, 2024

Psychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics – Psychedelic Alpha

Terran’s Fast Filing on 4-OH-DiPT Prodrug On Thursday July 13, 2023, a patent application titled Salts and Solid Forms of 4-Hydroxy-N,N-Diisopropyltryptamine Hemi-Glutarate and Hemi-Succinate was

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.